CDK12 and prostate cancer: The CDK12 results are striking given an alteration prevalence of 5% to 7% according to the literature and that limited clinical data indicate poor prognosis with minimal benefit from PARP inhibitor monotherapy in patients who have prostate cancer and CDK12 alterations27.